CD28 and cancer: Therefore, one of the effects of therapeutic monoclonal antibodies targeting CTLA-4 (interacting with CD28) and PD-L1 (interacting with PD-1), is allowing T-cells to maintain their increased glycolytic and glutaminolytic capacity to execute anti-cancer effector functions in the TME (113, 114).